These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10049794)

  • 1. Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat.
    Bergman K; Olofsson I; Sjöberg P
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):226-9. PubMed ID: 10049794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
    Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
    Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation.
    Monro AM; MacDonald JS
    Drug Saf; 1998 May; 18(5):309-19. PubMed ID: 9589843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenacetin and analgesic mixtures containing phenacetin.
    Rep Carcinog; 2004; 11():III212-3. PubMed ID: 21089942
    [No Abstract]   [Full Text] [Related]  

  • 8. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
    Osimitz TG; Droege W; Boobis AR; Lake BG
    Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Notice; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Mar; 78(52):16681-4. PubMed ID: 23530289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.
    van der Laan JW; Kasper P; Silva Lima B; Jones DR; Pasanen M
    Crit Rev Toxicol; 2016 Aug; 46(7):587-614. PubMed ID: 27116466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals.
    Contrera JF; Jacobs AC; DeGeorge JJ
    Regul Toxicol Pharmacol; 1997 Apr; 25(2):130-45. PubMed ID: 9185889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal carcinogenicity studies: 1. Poor human predictivity.
    Knight A; Bailey J; Balcombe J
    Altern Lab Anim; 2006 Feb; 34(1):19-27. PubMed ID: 16522147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
    McGregor D
    Crit Rev Toxicol; 2007; 37(10):887-914. PubMed ID: 18027166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS. Collaborative Study of the Micronucleus Group Test. Mammalian Mutagenicity Study Group.
    Morita T; Asano N; Awogi T; Sasaki YF; Sato S; Shimada H; Sutou S; Suzuki T; Wakata A; Sofuni T; Hayashi M
    Mutat Res; 1997 Feb; 389(1):3-122. PubMed ID: 9062586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medium-term bioassays as alternative carcinogenicity test.
    Ito N; Imaida K; Tamano S; Hagiwara A; Shirai T
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():103-6. PubMed ID: 9760442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies.
    Melnick RL; Thayer KA; Bucher JR
    Environ Health Perspect; 2008 Jan; 116(1):130-5. PubMed ID: 18197312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism.
    Counts JL; Goodman JI
    Regul Toxicol Pharmacol; 1995 Jun; 21(3):418-21. PubMed ID: 7480895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues in carcinogenicity testing: dose selection.
    Haseman JK
    Fundam Appl Toxicol; 1985 Feb; 5(1):66-78. PubMed ID: 3886467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.